Table 1.
Currently approved drugs for advanced melanoma.
| Drug | Type of Drug | Mechanism of Action |
|---|---|---|
| Nivolumab | Immune checkpoint inhibitors | PD-1 antagonist |
| Pembrolizumab | Immune checkpoint inhibitors | PD-1 antagonist |
| Ipilimumab | Immune checkpoint inhibitors | CTLA-4 antagonist |
| Nivolumab + Ipilimumab | Immune checkpoint inhibitors | PD-1 + CTLA-4 antagonist |
| Dabrafenib | Kinase inhibitor | Mutant BRAF |
| Trametinib | Kinase inhibitor | MEK |
| Vemurafenib | Kinase inhibitor | Mutant BRAF |
| Encorafenib + Binimetinib | Kinase inhibitor | Mutant BRAF and MEK |
| Trametinib + Dabrafenib | Kinase inhibitor | MEK and mutant BRAF |
| Cobimetinib + Vemurafenib | Kinase inhibitor | MEK and mutant BRAF |
| Talimogene laherparepvec | Oncologic virus | Virus-mediated GM-CSF production |
| Dacarbazine | Antineoplastic | Anti-mitotic and anti-metastatic |
| Aldesleukin | Cytokine | IL-2/IL-2R pathway |
| Peginterferon Alfa-2b | Cytokine | IFNAR1/2 pathway |
| High-dose Interferon Alfa-2b | Cytokine | IFNAR1/2 pathway |